CORDIS

EU research results

CORDIS

Towards enduring mouse resources and services advancing research into human health and disease

Fact Sheet

Reporting

Results

News & Multimedia

Project information

INFRAFRONTIER2020

Grant agreement ID: 730879

Project website

Status

Ongoing project

Start date

1 January 2017
End date

31 December 2020

Funded under:

H2020-EU.1.4.1.1.

Overall budget:

€ 4 968 252,16
EU contribution

€ 4 955 877,16

Coordinated by:

INFRAFRONTIER GMBH

Germany

Objective

The INFRAFRONTIER RI integrates European Mouse Clinics and the European Mouse Mutant Archive with the common goal to ensure access to mouse models for basic research of human health and disease, and to translate this knowledge into therapeutic approaches for the benefit of the European society.

The expanded INFRAFRONTIER2020 network, coordinated by the INFRAFRONTIER GmbH, includes 3 SMEs and is strategically responding to the INFRADEV3 call with aligned objectives to advance the long-term sustainability which are 1) development of business models and a stable legal framework; 2) raise awareness of the INFRAFRONTIER RI; 3) provide bespoke services aligned with user demands; 4) promote best practices in mouse phenogenomics; 5) enhance robustness of the INFRAFRONTIER IT infrastructure and use of the EMMA strain resource; and 6) improve business processes. Towards achieving these objectives key INFRAFRONTIER2020 project deliverables are:

• INFRAFRONTIER Business Plan2.0, and business models for all services
• Stable legal framework built on the INFRAFRONTIER legal entity
• INFRAFRONTIER annual stakeholder conferences
• Customised mouse model and secondary phenotyping pilot services
• INFRAFRONTIER advanced training schools in mouse phenogenomics
• Reengineered EMMA Database2.0 system
• Annotated mouse models of human diseases
• Quality management system for the legal entity

INFRAFRONTIER2020 will 1) enhance the sustainable operation of the INFRAFRONTIER RI; 2) continue to structure the ERA, 3) foster innovation, and 4) address major societal challenges in human health by customised service pilots supporting research into common and rare diseases. A sustainable INFRAFRONTIER RI will ensure the quality of deposited mice and support the reproducibility of biological results. Outreach efforts will raise awareness of resources and services and facilitate sustainable engagement with industry and global consortia such as the International Mouse Phenotyping Consortium

Programme(s)

H2020-EU.1.4.1.1. - Developing new world-class research infrastructures

Topic(s)

INFRADEV-03-2016-2017 - Individual support to ESFRI and other world-class research infrastructures

Call for proposal

H2020-INFRADEV-2016-1

See other projects for this call

Funding Scheme

CSA - Coordination and support action

Coordinator

INFRAFRONTIER GMBH

Address

Ingolstadter Landstrasse 1
85764 Neuherberg

Germany

Activity type

Private for-profit entities (excluding Higher or Secondary Education Establishments)

EU Contribution

€ 1 837 700

Website

Contact the organisation

Participants (29)

Sort alphabetically

Sort by EU Contribution

Expand all

HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM FUER GESUNDHEIT UND UMWELT GMBH

Germany

EU Contribution

€ 477 872,75

USTAV MOLEKULARNI GENETIKY AKADEMIE VED CESKE REPUBLIKY VEREJNA VYZKUMNA INSTITUCE

Czechia

EU Contribution

€ 195 528,13

OULUN YLIOPISTO

Finland

EU Contribution

€ 140 100

CENTRE EUROPEEN DE RECHERCHE EN BIOLOGIE ET MEDECINE

France

EU Contribution

€ 306 900

BIOMEDICAL SCIENCES RESEARCH CENTER ALEXANDER FLEMING

Greece

EU Contribution

€ 215 600

VETERINAERMEDIZINISCHE UNIVERSITAET WIEN

Austria

EU Contribution

€ 16 000

Toronto Centre for Phenogenomics Inc.

Canada

EUROPEAN MOLECULAR BIOLOGY LABORATORY

Germany

EU Contribution

€ 212 800

HELMHOLTZ-ZENTRUM FUR INFEKTIONSFORSCHUNG GMBH

Germany

EU Contribution

€ 12 800

MEDIZINISCHE HOCHSCHULE HANNOVER

Germany

EU Contribution

€ 17 600

TSE SYSTEMS GMBH

Germany

EU Contribution

€ 25 600

AYOXXA BIOSYSTEMS GMBH

Germany

EU Contribution

€ 20 800

KOBENHAVNS UNIVERSITET

Denmark

EU Contribution

€ 22 400

AGENCIA ESTATAL CONSEJO SUPERIOR DEINVESTIGACIONES CIENTIFICAS

Spain

EU Contribution

€ 72 625

UNIVERSIDAD AUTONOMA DE BARCELONA

Spain

EU Contribution

€ 12 800

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE

France

EU Contribution

€ 96 460,31

CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS

France

EU Contribution

€ 69 773,91

INSTITUT PASTEUR

France

EU Contribution

€ 42 600

BIOMEDCODE ELLAS ANONIMI ETERIA EPISTIMONIKIS KAI TEXNOLOGIKIS EREVNAS KAI EMBORIKIS EKMETALLEFSIS EPHARMOGON IATRIKIS

Greece

EU Contribution

€ 91 125

TEL AVIV UNIVERSITY

Israel

EU Contribution

€ 12 800

CONSIGLIO NAZIONALE DELLE RICERCHE

Italy

EU Contribution

€ 384 000

STICHTING HET NEDERLANDS KANKER INSTITUUT-ANTONI VAN LEEUWENHOEK ZIEKENHUIS

Netherlands

EU Contribution

€ 114 750

ACADEMISCH ZIEKENHUIS GRONINGEN

Netherlands

EU Contribution

€ 20 800

FUNDACAO CALOUSTE GULBENKIAN

Portugal

EU Contribution

€ 120 539,74

KAROLINSKA INSTITUTET

Sweden

EU Contribution

€ 77 321,38

UNITED KINGDOM RESEARCH AND INNOVATION

United Kingdom

EU Contribution

€ 227 905,94

MEDICAL RESEARCH COUNCIL

United Kingdom

GENOME RESEARCH LIMITED

United Kingdom

EU Contribution

€ 69 875

THE UNIVERSITY OF SHEFFIELD

United Kingdom

EU Contribution

€ 40 800

Project information

INFRAFRONTIER2020

Grant agreement ID: 730879

Project website

Status

Ongoing project

Start date

1 January 2017
End date

31 December 2020

Funded under:

H2020-EU.1.4.1.1.

Overall budget:

€ 4 968 252,16
EU contribution

€ 4 955 877,16

Coordinated by:

INFRAFRONTIER GMBH

Germany

Project information

INFRAFRONTIER2020

Grant agreement ID: 730879

Project website

Status

Ongoing project

Start date

1 January 2017
End date

31 December 2020

Funded under:

H2020-EU.1.4.1.1.

Overall budget:

€ 4 968 252,16
EU contribution

€ 4 955 877,16

Coordinated by:

INFRAFRONTIER GMBH

Germany

Periodic Reporting for period 1 - INFRAFRONTIER2020 (Towards enduring mouse resources and services advancing research into human health and disease)

Reporting period: 2017-01-01 to 2018-06-30

Summary of the context and overall objectives of the project

INFRAFRONTIER is the European Research Infrastructure for the generation, phenotyping, archiving and distribution of model mammalian genomes. The INFRAFRONTIER Research Infrastructure provides access to first-class tools and data for biomedical research, and thereby contributes to improving the understanding of gene function in human health and disease using the mouse model. The overall objective of the INFRAFRONTIER2020 project is to evolve INFRAFRONTIER towards a sustained and excellent operation. Further objectives are improving data management and fostering innovation potential. All project coordination, outreach, operations, data management, and service objectives are aligned with the EC Research Infrastructures Work Program, its call objectives, and expected impacts.

Work performed from the beginning of the project to the end of the period covered by the report and main results achieved so far

The INFRAFRONTIER2020 project was implemented by hiring experts supporting the professionalization of communication activities, the implementation of a quality management system, and the reengineering of the INFRAFRONTIER database. Overall, excellent progress was made, key milestones were achieved, and a data management plan was submitted as first deliverable. Project implementation was further supported by 12 networking meetings held in the first period, facilitating project specific and wider INFRAFRONTIER strategic discussions.

A major outreach activity was the inaugural INFRAFRONTIER Stakeholder Meeting held in Athens on November 14-16 2017, with a thematic focus on ‘Advancing Personalised Medicine with Animal Models’. The meeting targeted a wide range of INFRAFRONTIER stakeholders including Personalised Medicine initiatives, Rare Disease networks, funders, regulators and the INFRAFRONTIER user community, to discuss advances in CRISPR/Cas9 technology to model human conditions. The first INFRAFRONTIER Stakeholder Meeting was very successful and attracted 194 participants, 22 countries and 5 continents.

New INFRAFRONTIER activities to advance microbiome and ageing research with animal models were also supported with major outreach events. A satellite meeting to the Core Technologies in Life Sciences conference, held in Ghent on July 1st 2018 was organized entitled ‘Modelling the Mammalian Microbiota Host Superorganism - Current Tools and Challenges’. A conference with the same title was planned in the first reporting period and will be held at the Institute Pasteur, Paris, on October 15th-16th 2018. Conference details can be accessed at http://www.mam-2018.org/. INFRAFRONTIER engaged in the joint MouseAge Annual Meeting and the IUBMB focused meeting on ‘Molecular aspects of aging and longevity’, which was held in Athens on October 19th and 20th 2017, providing an excellent outreach opportunity to present INFRAFRONTIER resources and services to a large audience of ageing researchers. INFRAFRONTIER2020 partners contributed to the writing of a review on frailty biomarkers which will be published in Ageing Research Reviews.

The 2nd PHENOMIN Advanced Training School in mouse phenogenomics attracted 31 participants from France, Germany, UK, Switzerland, Czech Republic and Hungary.

To improve the overall operational performance and to provide a basis for sustainable development initiatives, INFRAFRONTIER2020 aims to adopt a quality management (QM) system for the INFRAFRONTIER legal entity. The utility and applicability of different quality management approaches were evaluated. It was decided to implement an ISO 9001:2015 compliant Quality Management System (QMS), and as a first step a thorough context analysis was carried out and a detailed process map of the INFRAFRONTIER legal entity was developed.

A robust IT infrastructure is the single most critical element to integrate operational activities in INFRAFRONTIER, and further supports the interfacing with the user community and thus the sustainability of the INFRAFRONTIER infrastructure. Since the EMMA database has been continuously developed since 2002, there is an urgent need for a new development cycle in order to increase performance and reliability. The INFRAFRONTIER database reengineering was initiated with a workshop in March 2017, where detailed requirements from experienced users of the INFRAFRONTIER network were compiled providing a solid foundation for the development of a new schema for the central INFRAFRONTIER database. The manual annotation and validation of INFRAFRONTIER-EMMA disease model resources is instrumental in increasing their robustness, global recognition and visibility and in promoting their global dissemination and use, thus effectively contributing to the overall sustainability of INFRAFRONTIER. During the first reporting period 633 strains distributed by INFRAFRONTIER/EMMA were annotated to match specific disease models described

Progress beyond the state of the art and expected potential impact (including the socio-economic impact and the wider societal implications of the project so far)

The INFRAFRONTIER2020 project will significantly enhance the sustainable operation of the INFRAFRONTIER RI and will continue to structure the ERA with an enlarged network and new Business Units. INFRAFRONTIER2020 will foster innovation and address the major societal challenge human health by new and customised service pilots supporting research into major common and rare diseases for its global user community. A sustainable INFRAFRONTIER RI will ensure the quality of deposited mice and supports the effort that biological results are reproducible. Outreach efforts will raise awareness of resources and services and inform stakeholders about the validity of mammalian models, their benefits and limitations, and the use of animal models in biomedical research. INFRAFRONTIER2020 will further facilitate the sustainable engagement with global consortia and networks driving the functional annotation of mammalian genomes.

00-if-twitter.png

Project information

INFRAFRONTIER2020

Grant agreement ID: 730879

Project website

Status

Ongoing project

Start date

1 January 2017
End date

31 December 2020

Funded under:

H2020-EU.1.4.1.1.

Overall budget:

€ 4 968 252,16
EU contribution

€ 4 955 877,16

Coordinated by:

INFRAFRONTIER GMBH

Project information

INFRAFRONTIER2020

Grant agreement ID: 730879

Project website

Status

Ongoing project

Start date

1 January 2017
End date

31 December 2020

Funded under:

H2020-EU.1.4.1.1.

Overall budget:

€ 4 968 252,16
EU contribution

€ 4 955 877,16

Coordinated by:

INFRAFRONTIER GMBH

Germany

Deliverables

Open Research Data Pilot (1)

Publications

Peer reviewed articles (1)

Towards frailty biomarkers: Candidates from genes and pathways regulated in aging and age-related diseases

Author(s): Ana Luisa Cardoso, Adelaide Fernandes, Juan Antonio Aguilar-Pimentel, Martin Hrabě de Angelis, Joana Ribeiro Guedes, Maria Alexandra Brito, Saida Ortolano, Giovambattista Pani, Sophia Athanasopoulou, Efstathios S. Gonos, Markus Schosserer, Johannes Grillari, Pärt Peterson, Bilge Guvenc Tuna, Soner Dogan, Angelika Meyer, Ronald van Os, Anne-Ulrike Trendelenburg

Published in: Ageing Research Reviews, Issue 47, 2018, Page(s) 214-277, ISSN 1568-1637

DOI: 10.1016/j.arr.2018.07.004

Project information

INFRAFRONTIER2020

Grant agreement ID: 730879

Project website

Status

Ongoing project

Start date

1 January 2017
End date

31 December 2020

Funded under:

H2020-EU.1.4.1.1.

Overall budget:

€ 4 968 252,16
EU contribution

€ 4 955 877,16

Coordinated by:

INFRAFRONTIER GMBH

Project information

INFRAFRONTIER2020

Grant agreement ID: 730879

Project website

Status

Ongoing project

Start date

1 January 2017
End date

31 December 2020

Funded under:

H2020-EU.1.4.1.1.

Overall budget:

€ 4 968 252,16
EU contribution

€ 4 955 877,16

Coordinated by:

INFRAFRONTIER GMBH

Germany

News

Scientific advances

Research on mice identifies new diabetes genes

22 March 2018

Project information

INFRAFRONTIER2020

Grant agreement ID: 730879

Project website

Status

Ongoing project

Start date

1 January 2017
End date

31 December 2020

Funded under:

H2020-EU.1.4.1.1.

Overall budget:

€ 4 968 252,16
EU contribution

€ 4 955 877,16

Coordinated by:

INFRAFRONTIER GMBH

Download

PDF

XML

Last update: 27 January 2020

Record number: 207430

Permalink: https://cordis.europa.eu/project/rcn/207430/en

CORDIS

Project information

Objective

Coordinator

Participants (29)

Project information

Project information

Periodic Reporting for period 1 - INFRAFRONTIER2020 (Towards enduring mouse resources and services advancing research into human health and disease)

Project information

Project information

Deliverables

Publications

Project information

Project information

News

Project information

Share this page

Download